Home LiteratureArticle Details
PMID: 27117833 Published · ppublish English Journal Article Review Research Support, N.I.H., Extramural

PD-L1 Expression in Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer ·Vol. 11 ·No. 7 ·2016-00-00 ·Pages 964-75

Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR

Abstract

Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein expression has emerged as a biomarker that predicts which patients are more likely to respond to immunotherapy. The understanding of PD-L1 as a biomarker is complicated by the history of use of different immunohistochemistry platforms with different PD-L1 antibodies, scoring systems, and positivity cut-offs for immunotherapy clinical trials with different anti-PD-L1 and anti-PD-1 drugs. Herein, we summarize the brief history of PD-L1 as a biomarker and describe the challenges remaining to harmonize PD-L1 detection and interpretation for best patient care.

Keywords
Biomarker Immunotherapy Lung cancer PD-L1
MeSH Terms
Animals B7-H1 Antigen/analysis,antagonists & inhibitors,immunology Biomarkers/analysis Humans Immunohistochemistry Immunotherapy Lung Neoplasms/chemistry,drug therapy Mice
Chemicals
B7-H1 Antigen Biomarkers CD274 protein, human
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Yu Hui
Department of Medicine/Medical Oncology, University of Colorado Cancer Center, University of Colorado, Denver, Colorado.
Boyle Theresa A
Department of Medicine/Medical Oncology, University of Colorado Cancer Center, University of Colorado, Denver, Colorado; Department of Pathology, University of Colorado, Denver, Colorado; Department of Pathology, Moffitt Cancer Center, Tampa, Florida; Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida.
Zhou Caicun
Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, People's Republic of China.
Rimm David L
Department of Pathology, Yale University, New Haven, Connecticut.
Hirsch Fred R
Department of Medicine/Medical Oncology, University of Colorado Cancer Center, University of Colorado, Denver, Colorado; Department of Pathology, University of Colorado, Denver, Colorado. Electronic address: Fred.Hirsch@ucdenver.edu.
References (66)
66 references, click to expand
  1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2015 Oct 22;373(17):1627-39 PMID: 26412456
  2. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
    Nature. 2014 Nov 27;515(7528):563-7 PMID: 25428504
  3. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
    J Thorac Oncol. 2015 Mar;10(3):426-30 PMID: 25384063
  4. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue.
    Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11982-7 PMID: 23818604
  5. Prognostic and predictive markers for the new immunotherapies.
    Oncology (Williston Park). 2014 Nov;28 Suppl 3:39-48 PMID: 25384886
  6. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.
    Tumori. 2012 Nov;98(6):751-5 PMID: 23389362
  7. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
    Ann Surg Oncol. 2016 Feb;23 (2):694-702 PMID: 26464193
  8. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Lancet. 2016 May 7;387(10031):1909-20 PMID: 26952546
  9. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
    Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):541-9 PMID: 26317305
  10. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.
    Nat Immunol. 2007 Mar;8(3):239-45 PMID: 17304234
  11. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.
    Oncotarget. 2015 Jun 10;6(16):14209-19 PMID: 25895031
  12. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
    Cancer Res. 2006 Apr 1;66(7):3381-5 PMID: 16585157
  13. CD28 and CTLA-4 coreceptor expression and signal transduction.
    Immunol Rev. 2009 May;229(1):12-26 PMID: 19426212
  14. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.
    Cancer Res. 2013 Jan 1;73(1):128-38 PMID: 23135914
  15. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2015 Jun 20;33(18):2004-12 PMID: 25897158
  16. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
    J Clin Oncol. 2010 Jul 1;28(19):3167-75 PMID: 20516446
  17. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
    Nature. 2014 Nov 27;515(7528):568-71 PMID: 25428505
  18. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
    Cancer Discov. 2013 Dec;3(12):1355-63 PMID: 24078774
  19. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
    Science. 2015 Apr 3;348(6230):124-8 PMID: 25765070
  20. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    N Engl J Med. 2012 Jun 28;366(26):2443-54 PMID: 22658127
  21. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.
    Blood. 2014 Mar 27;123(13):2062-5 PMID: 24497532
  22. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
    J Thorac Oncol. 2017 Feb;12 (2):208-222 PMID: 27913228
  23. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
    Ann Oncol. 2014 Oct;25(10):1935-40 PMID: 25009014
  24. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Arch Pathol Lab Med. 2014 Feb;138(2):241-56 PMID: 24099077
  25. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
    Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174-9 PMID: 15569934
  26. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    PLoS One. 2015 Aug 27;10(8):e0136023 PMID: 26313362
  27. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
    J Clin Oncol. 2015 May 1;33(13):1430-7 PMID: 25452452
  28. PD-L1 expression in small cell neuroendocrine carcinomas.
    Eur J Cancer. 2015 Feb;51(3):421-6 PMID: 25582496
  29. PD-L1 expression in small cell lung cancer.
    Eur J Cancer. 2015 Sep;51(13):1853-5 PMID: 26148861
  30. CTLA-4 control over Foxp3+ regulatory T cell function.
    Science. 2008 Oct 10;322(5899):271-5 PMID: 18845758
  31. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
    JAMA Oncol. 2016 Jan;2(1):46-54 PMID: 26562159
  32. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.
    J Vis Exp. 2013 Jan 03;(71):null PMID: 23328703
  33. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
    Cancer. 2005 Nov 15;104(10):2084-91 PMID: 16208700
  34. Differential binding properties of B7-H1 and B7-DC to programmed death-1.
    Biochem Biophys Res Commun. 2003 Aug 1;307(3):672-7 PMID: 12893276
  35. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
    N Engl J Med. 2013 Jul 11;369(2):134-44 PMID: 23724846
  36. Nivolumab in previously untreated melanoma without BRAF mutation.
    N Engl J Med. 2015 Jan 22;372(4):320-30 PMID: 25399552
  37. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
    Lancet Oncol. 2015 Mar;16(3):257-65 PMID: 25704439
  38. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Eur J Cancer. 2015 Nov;51(17):2698-707 PMID: 26329973
  39. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.
    Med Oncol. 2011 Sep;28(3):682-8 PMID: 20373055
  40. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
    Nat Immunol. 2001 Mar;2(3):261-8 PMID: 11224527
  41. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
    Lancet. 2016 Apr 9;387(10027):1540-50 PMID: 26712084
  42. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
    J Clin Oncol. 2016 Mar 10;34(8):833-42 PMID: 26755520
  43. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Eur J Cancer. 2014 May;50(7):1361-9 PMID: 24548766
  44. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
    J Exp Med. 2000 Oct 2;192(7):1027-34 PMID: 11015443
  45. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Clin Lung Cancer. 2015 Sep;16(5):e25-35 PMID: 25801750
  46. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
    Sci Transl Med. 2013 Aug 28;5(200):200ra116 PMID: 23986400
  47. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics.
    Thorac Cancer. 2015 Jul;6(4):534-8 PMID: 26273411
  48. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
    Nature. 2014 Nov 27;515(7528):558-62 PMID: 25428503
  49. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Lung Cancer. 2015 Apr;88(1):24-33 PMID: 25662388
  50. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
    J Thorac Oncol. 2015 Dec;10 (12 ):1726-35 PMID: 26473645
  51. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.
    Nat Med. 1999 Dec;5(12):1365-9 PMID: 10581077
  52. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    N Engl J Med. 2015 Jul 9;373(2):123-35 PMID: 26028407
  53. Pembrolizumab for the treatment of non-small-cell lung cancer.
    N Engl J Med. 2015 May 21;372(21):2018-28 PMID: 25891174
  54. Programmed death ligand-1 expression in non-small cell lung cancer.
    Lab Invest. 2014 Jan;94(1):107-16 PMID: 24217091
  55. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
    Clin Cancer Res. 2014 Oct 1;20(19):5064-74 PMID: 24714771
  56. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
    J Thorac Oncol. 2015 Jul;10(7):985-9 PMID: 26134220
  57. PD-L1 expression is increased in a subset of basal type breast cancer cells.
    PLoS One. 2014 Feb 14;9(2):e88557 PMID: 24551119
  58. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
    N Engl J Med. 2015 Jul 2;373(1):23-34 PMID: 26027431
  59. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
    Sci Transl Med. 2012 Mar 28;4(127):127ra37 PMID: 22461641
  60. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
    N Engl J Med. 2015 Jun 25;372(26):2509-20 PMID: 26028255
  61. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    J Clin Oncol. 2013 Nov 1;31(31):3997-4013 PMID: 24101045
  62. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
    Nat Med. 2002 Aug;8(8):793-800 PMID: 12091876
  63. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma.
    Onco Targets Ther. 2014 Apr 12;7:567-73 PMID: 24748806
  64. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.
    J Thorac Oncol. 2014 Feb;9(2):144-53 PMID: 24419410
  65. Expression of programmed death 1 ligands by murine T cells and APC.
    J Immunol. 2002 Nov 15;169(10):5538-45 PMID: 12421930
  66. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
    N Engl J Med. 2012 Jun 28;366(26):2455-65 PMID: 22658128
Article Info
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Abbr.
J Thorac Oncol
ISSN
1556-1380
DOI
10.1016/j.jtho.2016.04.014
Email
fred.hirsch@ucdenver.edu
Published
2016-00-00
Epub
2016-00-23
Pages
964-75
Language
English
Region
United States
NLM ID
101274235
PMCID
PMC5353357
Subset
IM
Grants
NCI NIH HHS · P50 CA058187 · United States
NCATS NIH HHS · UL1 TR001863 · United States
Corrections
ErratumIn
PMID: 27988099
External Links
PubMed source DOI: 10.1016/j.jtho.2016.04.014 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2